Back

Sacubitril/valsartan compared to valsartan in regressing myocardial fibrosis in stage B heart failure: the REVERSE-LVH Trial

1 September 2024 (16:39 - 16:51)
Organised by: Logo
Congress Presentation Part of: Smaller trials: cardiac function and remodelling Myocardial Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Calvin Chin

National Heart Centre Singapore, Singapore (Singapore)

4 More presentations in this session

Presentation thumbnail
Strain sUrveillance during Chemotherapy for improving Cardiovascular Outcomes: Results of a Randomized Trial of Cardioprotection for Reduced Myocardial Strain (SUCCOUR-MRI)
Professor T. Marwick (Melbourne, AU)
Slides Video
Presentation thumbnail
Catheter Ablation versus Medical Rate Control in Atrial Fibrillation with Left Ventricular Systolic Dysfunction and Myocardial Fibrosis - The CAMERA-MRI II Randomized Trial
Associate Professor S. Prabhu (Melbourne, AU)
Slides Video
Presentation thumbnail
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction
Doctor J. Carberry (Glasgow, GB)
Slides Video
Presentation thumbnail
Sacubitril/valsartan in primary prevention of cancer-therapy related cardiac dysfunction in breast cancer patients.
Doctor Y. Hsu (Tainan, TW)
Slides Video

Access the full session

Session thumbnail
Smaller trials: cardiac function and remodelling
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 16:39 CET
You may be interested in
thumbnail
Congress Presentation
ENVAD-HF: sacubitril/valsartan in Heartmate 3 LVAD recipients
thumbnail
Congress Session
Smaller trials: cardiac function and remodelling
thumbnail
Congress Session
Hottest trials (1)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources